MD Anderson and Mirati Therapeutics announce KRAS strategic research and development collaboration in solid tumors

HOUSTON and San Diego, Calif? The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in…

Why Black men’s prostate cancer may be more responsive to immunotherapy

Increased level of plasma cells linked to improved cancer survival 1,300 prostate tumor samples studied Immunotherapy-based precision medicine clinical trials being developed CHICAGO— Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits from immunotherapy treatment. A new Northwestern Medicine study discovered the reason appears to be an increase of…

Rabies treatment demonstrated as safe and effective for use in children in first pediatric trial

A treatment, known as KEDRAB (Rabies Immune Globulin [Human]), currently used in the prevention of rabies has been demonstrated to be safe and effective for patients age 17 and under. Results published today in Human Vaccines & Immunotherapeutics report the first and only pediatric trial of any human rabies immunoglobulin (HRIG) currently available in the…

HIV research yields potential drug target

SAN ANTONIO — Humans possess a formidable multi-layered defense system that protects us against viral infections. Better understanding of these defenses and the tricks that viruses use to evade them could open novel avenues for treating viral infections and possibly other diseases. For example, a human protein called SAMHD1 impedes replication of the human immunodeficiency…